Casgevy sickle cell gene therapy is now FDA-approved for children as young as two, opening access for 5,500 more U.S. kids.
Recent data published in NEJM demonstrates that CRISPR gene-editing therapy achieves complete clinical efficacy endpoints in ...
Is NTLA a good stock to buy? We came across a bullish thesis on Intellia Therapeutics, Inc. on Markman Capital Insight’s ...
Biomedical Engineering Is the Backbone of Modern Medical Advancement and the Biomedical Engineering Society (BMES) is ...
Morning Overview on MSN
A single gene-editing infusion cut severe swelling attacks by 87 percent in a trial
People living with hereditary angioedema, a rare genetic condition that triggers sudden, painful swelling of the face, throat ...
CRISPR Therapeutics wins FDA pediatric approval for Casgevy, boosting market potential and pipeline upside despite slow uptake. Click here to read more.
The cancer biologics market presents significant opportunities driven by a rising global cancer incidence, increased R&D in personalized medicine, and advancements in biologic therapies like mRNA and ...
The Gene Editing Therapeutics market, driven by advancements in CRISPR technology and precision medicine, presents opportunities in oncology, rare genetic disorders, and chronic diseases. Investment ...
An extremely precise genome editing technique called base editing has been used for the first time by Cambridge scientists to ...
Researchers have spent decades-and billions of dollars-sequencing animal and crop genomes, but fungi have historically been the forgotten middle child of genomics, only noticed when they're ruining ...
The FDA on Wednesday expanded the approval for exagamglogene autotemcel (exa-cel, Casgevy) in severe sickle cell disease with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results